(EXPO) Exponent - Ratings and Ratios
Consulting, Analysis, Testing, Risk
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.57% |
| Yield on Cost 5y | 1.37% |
| Yield CAGR 5y | 10.67% |
| Payout Consistency | 100.0% |
| Payout Ratio | 59.4% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 26.3% |
| Value at Risk 5%th | 39.1% |
| Relative Tail Risk | -9.63% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.88 |
| Alpha | -28.80 |
| CAGR/Max DD | -0.20 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.303 |
| Beta | 0.539 |
| Beta Downside | 0.239 |
| Drawdowns 3y | |
|---|---|
| Max DD | 42.55% |
| Mean DD | 22.07% |
| Median DD | 21.18% |
Description: EXPO Exponent January 11, 2026
Exponent, Inc. (NASDAQ: EXPO) is a science- and engineering-consulting firm that serves a broad spectrum of industries through two operating segments: Engineering & Other Scientific, and Environmental & Health.
The Engineering segment delivers expertise in biomechanics, biomedical engineering, civil/structural engineering, data science, electrical/computer engineering, materials science, mechanical engineering, polymer chemistry, thermal sciences, and vehicle engineering. The Environmental & Health segment focuses on chemical regulation, food safety, ecological and biological sciences, environmental and earth sciences, and health sciences, plus proactive/reactive product safety, litigation support, and regulatory services.
Key customers span chemicals, construction, consumer products, energy, food & beverage, government, life sciences, insurance, manufacturing, technology, industrial equipment, and transportation, reflecting the firm’s diversified revenue base.
Recent performance highlights (FY 2023) include revenue of approximately $1.0 billion, an operating margin near 13 %, and a backlog exceeding $1.2 billion, indicating strong demand for consulting services amid heightened ESG compliance and rising product-liability litigation. The sector is further buoyed by increased regulatory scrutiny in chemicals and food safety, which drives steady growth for firms with deep technical expertise.
For a deeper quantitative assessment, you might explore ValueRay’s analyst notes on EXPO.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 104.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA -4.49 > 1.0 |
| NWC/Revenue: 45.86% < 20% (prev 49.17%; Δ -3.31% < -1%) |
| CFO/TA 0.17 > 3% & CFO 132.2m > Net Income 104.8m |
| Net Debt (-124.8m) to EBITDA (149.5m): -0.83 < 3 |
| Current Ratio: 2.69 > 1.5 & < 3 |
| Outstanding Shares: last quarter (51.5m) vs 12m ago -0.33% < -2% |
| Gross Margin: 40.33% > 18% (prev 0.45%; Δ 3989 % > 0.5%) |
| Asset Turnover: 75.90% > 50% (prev 75.12%; Δ 0.78% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
Altman Z'' 8.29
| A: 0.34 (Total Current Assets 416.8m - Total Current Liabilities 154.8m) / Total Assets 761.4m |
| B: 0.87 (Retained Earnings 658.8m / Total Assets 761.4m) |
| C: 0.19 (EBIT TTM 144.5m / Avg Total Assets 752.8m) |
| D: 1.83 (Book Value of Equity 656.5m / Total Liabilities 358.6m) |
| Altman-Z'' Score: 8.29 = AAA |
Beneish M -2.87
| DSRI: 1.06 (Receivables 182.0m/168.6m, Revenue 571.4m/559.0m) |
| GMI: 1.11 (GM 40.33% / 44.60%) |
| AQI: 1.06 (AQ_t 0.26 / AQ_t-1 0.25) |
| SGI: 1.02 (Revenue 571.4m / 559.0m) |
| TATA: -0.04 (NI 104.8m - CFO 132.2m) / TA 761.4m) |
| Beneish M-Score: -2.87 = A |
ValueRay F-Score (Strict, 0-100) 80.74
| 1. Piotroski: 6.0pt |
| 2. FCF Yield: 3.37% |
| 3. FCF Margin: 21.51% |
| 4. Debt/Equity: 0.21 |
| 5. Debt/Ebitda: -0.83 |
| 6. ROIC - WACC: 16.94% |
| 7. RoE: 24.77% |
| 8. Revenue Trend: 66.19% |
| 9. EPS Trend: -36.60% |
What is the price of EXPO shares?
Over the past week, the price has changed by -0.43%, over one month by +2.95%, over three months by +8.12% and over the past year by -18.47%.
Is EXPO a buy, sell or hold?
- Strong Buy: 1
- Buy: 0
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the EXPO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 85.5 | 15.1% |
| Analysts Target Price | 85.5 | 15.1% |
| ValueRay Target Price | 75.4 | 1.6% |
EXPO Fundamental Data Overview January 19, 2026
P/E Forward = 33.4448
P/S = 7.0911
P/B = 9.2354
P/EG = 3.14
Revenue TTM = 571.4m USD
EBIT TTM = 144.5m USD
EBITDA TTM = 149.5m USD
Long Term Debt = 82.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 6.49m USD (from shortTermDebt, last quarter)
Debt = 82.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -124.8m USD (from netDebt column, last quarter)
Enterprise Value = 3.64b USD (3.77b + Debt 82.6m - CCE 207.4m)
Interest Coverage Ratio = unknown (Ebit TTM 144.5m / Interest Expense TTM 0.0)
EV/FCF = 29.63x (Enterprise Value 3.64b / FCF TTM 122.9m)
FCF Yield = 3.37% (FCF TTM 122.9m / Enterprise Value 3.64b)
FCF Margin = 21.51% (FCF TTM 122.9m / Revenue TTM 571.4m)
Net Margin = 18.35% (Net Income TTM 104.8m / Revenue TTM 571.4m)
Gross Margin = 40.33% ((Revenue TTM 571.4m - Cost of Revenue TTM 340.9m) / Revenue TTM)
Gross Margin QoQ = 24.94% (prev 16.43%)
Tobins Q-Ratio = 4.78 (Enterprise Value 3.64b / Total Assets 761.4m)
Interest Expense / Debt = 7.77% (Interest Expense 6.42m / Debt 82.6m)
Taxrate = 27.38% (10.6m / 38.6m)
NOPAT = 105.0m (EBIT 144.5m * (1 - 27.38%))
Current Ratio = 2.69 (Total Current Assets 416.8m / Total Current Liabilities 154.8m)
Debt / Equity = 0.21 (Debt 82.6m / totalStockholderEquity, last quarter 402.9m)
Debt / EBITDA = -0.83 (Net Debt -124.8m / EBITDA 149.5m)
Debt / FCF = -1.02 (Net Debt -124.8m / FCF TTM 122.9m)
Total Stockholder Equity = 423.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 13.93% (Net Income 104.8m / Total Assets 761.4m)
RoE = 24.77% (Net Income TTM 104.8m / Total Stockholder Equity 423.3m)
RoCE = 28.57% (EBIT 144.5m / Capital Employed (Equity 423.3m + L.T.Debt 82.6m))
RoIC = 24.79% (NOPAT 105.0m / Invested Capital 423.3m)
WACC = 7.85% (E(3.77b)/V(3.85b) * Re(7.90%) + D(82.6m)/V(3.85b) * Rd(7.77%) * (1-Tc(0.27)))
Discount Rate = 7.90% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 0.01%
[DCF Debug] Terminal Value 78.29% ; FCFF base≈135.1m ; Y1≈131.9m ; Y5≈132.9m
Fair Price DCF = 50.97 (EV 2.42b - Net Debt -124.8m = Equity 2.54b / Shares 49.9m; r=7.85% [WACC]; 5y FCF grow -3.46% → 2.90% )
EPS Correlation: -36.60 | EPS CAGR: -48.68% | SUE: -4.0 | # QB: 0
Revenue Correlation: 66.19 | Revenue CAGR: 3.89% | SUE: 1.02 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.55 | Chg30d=+0.002 | Revisions Net=+2 | Analysts=3
EPS next Year (2026-12-31): EPS=2.23 | Chg30d=-0.120 | Revisions Net=+3 | Growth EPS=+8.4% | Growth Revenue=+7.5%
Additional Sources for EXPO Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle